<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149291</url>
  </required_header>
  <id_info>
    <org_study_id>P12-314</org_study_id>
    <nct_id>NCT01149291</nct_id>
  </id_info>
  <brief_title>A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism</brief_title>
  <official_title>A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this post-marketing observational study is to obtain further data on the long term
      use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in
      the normal clinical setting and according to the approved Summary of Product Characteristics
      for the treatment of secondary hyperparathyroidism in hemodialysis patients in Turkey. The
      relation of the safety data to PTH (Parathyroid hormone) suppression over time will be
      evaluated. Also the number and incidence of hypercalcemia and hyperphosphatemia will be
      recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The scientific purpose of this study is to obtain data on the use of sVDRA(Selective Vitamin
      D Receptor Activator) in real-life clinical practice. This study will allow us to observe
      drug effectiveness in a distinct geography. Treatment effects, as well as maintenance of the
      results will be recorded for a 18 months period in order to obtain experience in the long
      term use of sVDRA(Selective Vitamin D Receptor Activator). Furthermore in the centers,
      additional blood parameter, hsCRP (high sensitivity C-reactive protein), will be examined as
      part of the clinical routine.

      The primary aim of the study is:

        -  To assess percentage change in iPTH (intact parathyroid hormone) level monthly among
           hemodialysis patients with sHPT (secondary hyperparathyroidism) receiving sVDRA
           (Selective Vitamin D Receptor Activator) therapy.

      Secondary aims are:

        -  To observe changes in commonly assessed biochemical parameters for bone and mineral
           metabolism (Ca (Calcium), P (Phosphorus), ALP (Alkaline phosphatase) and additionally
           hsCRP (high sensitivity C-reactive protein) as cardiovascular inflammatory marker.

        -  To evaluate routinely checked parameters like albumin, hemoglobin and dialysis adequacy
           (KT/V).

        -  To collect and evaluate data from all adverse events in order to establish the safety
           profile of sVDRA(Selective Vitamin D Receptor Activator) in daily clinical practice.

        -  To collect mortality data 6 months after 12 months of observational period or 6 months
           after drop out.

      Patients will be followed for 12 months within the post-marketing observational study and
      will be checked for mortality data 6 months after this follow up period. The enrollment
      period should not exceed 6 months.

      All demographic information will be summarized by using descriptive statistics and graphs.
      Laboratory levels will be assessed by using mean, median, minimum, maximum, standard
      deviation and percentages on visit basis. The mean differences on laboratory levels between
      visits will also be summarized by graphics and assessed by using percentages.

      Alkaline phosphatase and hsCRP (high sensitivity C-reactive protein) levels will also be
      summarized by using descriptive statistics and graphs per visit.

      sVDRA (Selective Vitamin D Receptor Activator) dose changes per visits will be summarized by
      descriptive statistics and graphs.

      Mortality will be analyzed with life tables. By taking into account the primary and secondary
      aims of the study, to be able to achieve the therapeutic success on iPTH (intact parathyroid
      hormone) level changes with sVDRA (Selective Vitamin D Receptor Activator) treatment and
      perform mortality assessment in following 6 months and collect data regarding safety and
      efficacy of sVDRAs (Selective Vitamin D Receptor Activators) in long term use, it has been
      determined to enroll totally 510 patients from 30 sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess percentage change in iPTH (intact Parathyroid Hormone) level monthly among hemodialysis patients with SHPT (Secondary Hyperparathyroidism) receiving sVDRA (Selective Vitamin D Receptor Activator) therapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium, Phosphorus, ALP (Alkaline Phosphatase)</measure>
    <time_frame>After early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin, hemoglobin and dialysis adequacy (KT/V)</measure>
    <time_frame>After early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP (High Sensitivity C-Reactive Protein)</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP (High Sensitivity C-Reactive Protein)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP (High Sensitivity C-Reactive Protein)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP (High Sensitivity C-Reactive Protein)</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP (High Sensitivity C-Reactive Protein)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP (High Sensitivity C-Reactive Protein)</measure>
    <time_frame>After early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality data</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">511</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>End stage renal disease patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        ESRD (End Stage Renal Disease) patients undergoing hemodialysis who at the time of entry
        are receiving sVDRA's (Selective Vitamin D Receptor Activator) as it is prescribed in the
        normal clinical setting and according to the approved SmPC (Summary of Product
        Characteristics) for the prevention or treatment of secondary hyperparathyroidism.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with secondary hyperparathyroidism in the presence of chronic kidney disease
             stage 5 and receiving hemodialysis who is treated with sVDRA's (Selective Vitamin D
             Receptor Activator) injection

          -  iPTH (intact parathyroid hormone) &gt;300pg/ml, corrected serum Ca (Calcium) &lt; 10.2
             mg/dl, serum P (Phosphorus) &lt; 6 mg/dl

          -  Male and female (not pregnant or not planning to be pregnant in the next 12 months)
             patients equal to or older than 18 years of age

          -  Signed Informed consent by subject

          -  Hypertensive and Diabetic subjects must be on an optimal and steady medication regimen
             for more than 30 days

        Exclusion Criteria:

          -  Subject has known hypersensitivity and/or toxicity to vitamin D metabolites and/or
             other product ingredients

          -  Subject has participated in a clinical study within the last month

          -  If sVDRA's (Selective Vitamin D Receptor Activator) are contraindicated according to
             the SmPC (Summary of Product Characteristics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmut Gucuk, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37822</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 68286</name>
      <address>
        <city>Antalya</city>
        <zip>7130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40677</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 85153</name>
      <address>
        <city>Istanbul</city>
        <zip>34180</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40672</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40674</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40678</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40686</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 61585</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63764</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63765</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63766</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 69973</name>
      <address>
        <city>Ä°stanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63763</name>
      <address>
        <city>Izmir</city>
        <zip>7070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48127</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 64444</name>
      <address>
        <city>Karaman</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40684</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48132</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 68283</name>
      <address>
        <city>Kutahya</city>
        <zip>43260</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 68281</name>
      <address>
        <city>Mersin</city>
        <zip>33000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 68282</name>
      <address>
        <city>Mersin</city>
        <zip>33000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 69974</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>January 9, 2015</last_update_submitted>
  <last_update_submitted_qc>January 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high sensitivity C-reactive protein (hsCRP)</keyword>
  <keyword>cardiorenal</keyword>
  <keyword>end stage renal disease (ESRD)</keyword>
  <keyword>Secondary hyperparathyroidism (SHPT)</keyword>
  <keyword>dialysis</keyword>
  <keyword>paricalcitol</keyword>
  <keyword>osteodystrophy</keyword>
  <keyword>selective Vitamin D receptor activators (sVDRA)</keyword>
  <keyword>chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

